Rheumatoid Arthritis

First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002–2011: data from the NOR-DMARD register
Elisabeth Lie, Karen M Fagerli, Knut Mikkelsen, Erik Rødevand, Åse Lexberg, Synøve Kalstad, Till Uhlig, Tore K Kvien

Annals of the Rheumatic Diseases Oct 2014, 73 (10) 1905-1906; DOI: 10.1136/annrheumdis-2014-205490
No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment
Elizabeth V Arkema, Nils Feltelius, Tomas Olsson, Johan Askling

Annals of the Rheumatic Diseases Nov 2014, 73 (11) 2061-2062; DOI: 10.1136/annrheumdis-2014-205622
Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register
Ibrahim Ibrahim, Jennifer Humphreys, Ibtisam Mokhtar, Tarnya Marshall, Suzanne Verstappen, Deborah Symmons, Sebastien Viatte, Anne Barton, Darren Plant

Annals of the Rheumatic Diseases Nov 2015, 74 (11) 2099-2102; DOI: 10.1136/annrheumdis-2015-207851
Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice
Eva L Kneepkens, Chamaida Plasencia, Charlotte LM Krieckaert, Dora Pascual-Salcedo, Desiree van der Kleij, Michael T Nurmohamed, M Teresa López-Casla, Roeland Wieringa, Theo Rispens, Gertjan Wolbink

Annals of the Rheumatic Diseases Dec 2014, 73 (12) 2217-2219; DOI: 10.1136/annrheumdis-2014-205983
Proposal for a new nomenclature of disease-modifying antirheumatic drugs
Josef S Smolen, Désirée van der Heijde, Klaus P Machold, Daniel Aletaha, Robert Landewé

Annals of the Rheumatic Diseases Jan 2014, 73 (1) 3-5; DOI: 10.1136/annrheumdis-2013-204317
Forget personalised medicine and focus on abating disease activity
Josef S Smolen, Daniel Aletaha

Annals of the Rheumatic Diseases Jan 2013, 72 (1) 3-6; DOI: 10.1136/annrheumdis-2012-202361
Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis
Rachel Knevel, Jessica Annemarie Bernadette van Nies, S le Cessie, Tom W J Huizinga, E Brouwer, Annette H M van der Helm-van Mil

Annals of the Rheumatic Diseases Feb 2013, 72 (2) 307-308; DOI: 10.1136/annrheumdis-2012-201931
Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection
Ioannnis Mitroulis, Chrisoula Hatzara, Anna Kandili, Emilia Hadziyannis, Dimitrios Vassilopoulos

Annals of the Rheumatic Diseases Feb 2013, 72 (2) 308-310; DOI: 10.1136/annrheumdis-2012-202088
A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study
Hideto Kameda, Katsuaki Kanbe, Eri Sato, Yukitaka Ueki, Kazuyoshi Saito, Shouhei Nagaoka, Toshihiko Hidaka, Tatsuya Atsumi, Michishi Tsukano, Tsuyoshi Kasama, Shunichi Shiozawa, Yoshiya Tanaka, Hisashi Yamanaka, Tsutomu Takeuchi

Annals of the Rheumatic Diseases Feb 2013, 72 (2) 310-312; DOI: 10.1136/annrheumdis-2012-201804
Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort
Jérémie Sellam, Salma Kotti, Soraya Fellahi, Jean-Philippe Bastard, Magali Meyer, Frédéric Lioté, Olivier Meyer, Tabassome Simon, Jacqueline Capeau, Francis Berenbaum

Annals of the Rheumatic Diseases Feb 2013, 72 (2) 312-314; DOI: 10.1136/annrheumdis-2012-202119

Main menu

Rheumatoid Arthritis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Rheumatoid Arthritis

Pages